{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:07:09Z","timestamp":1759018029488,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.ophtha.2006.10.038","type":"journal-article","created":{"date-parts":[[2007,2,17]],"date-time":"2007-02-17T07:03:27Z","timestamp":1171695807000},"page":"847-854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Relative Cost of a Line of Vision in Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"114","author":[{"given":"William E.","family":"Smiddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2006.10.038_bib1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/archopht.1982.01030030920003","article-title":"Argon laser photocoagulation for senile macular degeneration: results of a randomized clinical trial","volume":"100","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib2","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1001\/archopht.1990.01070080058036","article-title":"Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration: results of a randomized clinical trial","volume":"108","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/archopht.1991.01080080069030","article-title":"Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib4","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/archopht.1991.01080090044025","article-title":"Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials\u2014TAP report 1","volume":"117","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ophtha.2004.08.012","article-title":"Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization","volume":"112","author":"Spaide","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2006.10.038_bib8","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2006.10.038_bib9","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/archopht.1979.01020010310003","article-title":"Four risk factors for severe visual loss in diabetic retinopathy: the third report from the Diabetic Retinopathy Study","volume":"97","year":"1979","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib11","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.1985.01050110038020","article-title":"Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial Diabetic Retinopathy Vitrectomy Study report 2","volume":"103","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib12","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0161-6420(88)33015-0","article-title":"Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: results of a randomized trial\u2014Diabetic Retinopathy Vitrectomy Study report 3","volume":"95","year":"1988","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2006.10.038_bib13","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1","volume":"103","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib14","first-page":"475","article-title":"Recovery of visual acuity after retinal detachment involving the macula","volume":"80","author":"Burton","year":"1982","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2006.10.038_bib15","first-page":"OP499","article-title":"Preoperative factors influencing anatomic success rates following retinal detachment surgery","volume":"83","author":"Burton","year":"1977","journal-title":"Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3928\/1542-8877-19970901-04","article-title":"Macular hole surgery without using adjunctive additives","volume":"28","author":"Smiddy","year":"1997","journal-title":"Ophthalmic Surg Lasers"},{"key":"10.1016\/j.ophtha.2006.10.038_bib17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0002-9394(00)00358-5","article-title":"Internal limiting membrane removal in the management of full-thickness macular holes","volume":"129","author":"Mester","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib18","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/S0161-6420(00)00331-6","article-title":"Macular hole surgery with and without internal limiting membrane peeling","volume":"107","author":"Brooks","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2006.10.038_bib19","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0161-6420(93)31419-3","article-title":"Vitreous surgery for macular holes","volume":"100","author":"Wendel","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2006.10.038_bib20","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0161-6420(84)34136-7","article-title":"Vitrectomy for macular pucker","volume":"91","author":"Michels","year":"1984","journal-title":"Ophthalmology"},{"year":"2002","series-title":"Period life table","key":"10.1016\/j.ophtha.2006.10.038_bib21"},{"key":"10.1016\/j.ophtha.2006.10.038_bib22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ajo.2005.11.058","article-title":"Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration","volume":"141","author":"Augustin","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00006982-200210000-00002","article-title":"Effects of verteporfin therapy on contrast sensitivity: results from the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Investigation\u2014TAP report no. 4","volume":"22","author":"Rubin","year":"2002","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2006.10.038_bib24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0161-6420(90)32573-3","article-title":"Detecting and treating retinopathy in patients with type I diabetes mellitus: a health policy model","volume":"97","author":"Javitt","year":"1990","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2006.10.038_bib25","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S0161-6420(95)30808-1","article-title":"Vitrectomy for complications of proliferative diabetic retinopathy: functional outcomes","volume":"102","author":"Smiddy","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2006.10.038_bib26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0161-6420(96)30676-3","article-title":"Bilateral visual function following macular surgery","volume":"103","author":"Polk","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2006.10.038_bib27","first-page":"32","article-title":"Assessing quality of life: beyond the Snellen chart","year":"2004","journal-title":"Eyenet"},{"key":"10.1016\/j.ophtha.2006.10.038_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0002-9394(99)00108-7","article-title":"Quality of life of low-vision patients and the impact of low-vision services","volume":"128","author":"Scott","year":"1999","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2006.10.038_bib29","first-page":"1","article-title":"The economic realities of photodynamic therapy for treatment of AMD","volume":"13","author":"William","year":"2004","journal-title":"Vitreoretinal surgery and techniques"},{"key":"10.1016\/j.ophtha.2006.10.038_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/archopht.118.1.47","article-title":"Utility values and age-related macular degeneration","volume":"118","author":"Brown","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0008-4182(00)80005-8","article-title":"Difference between ophthalmologists\u2019 and patients\u2019 perceptions of quality of life associated with age-related macular degeneration","volume":"35","author":"Brown","year":"2000","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/bjo.85.3.327","article-title":"Utility values associated with blindness in an adult population","volume":"85","author":"Brown","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib33","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0161-6420(01)00764-3","article-title":"The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration","volume":"108","author":"Sharma","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2006.10.038_bib34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archopht.120.4.481","article-title":"Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration","volume":"120","author":"Brown","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0039-6257(02)00457-5","article-title":"Health care economic analyses and value-based medicine","volume":"48","author":"Brown","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/bjo.87.3.259","article-title":"Utilities associated with diabetic retinopathy: results from a Canadian sample","volume":"87","author":"Sharma","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib37","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/bjo.2003.039131","article-title":"Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration","volume":"88","author":"Hopley","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2006.10.038_bib38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1055\/s-2005-858315","article-title":"Treatment of neovascular age-related macular degeneration with ranibizumab\/Lucentis","volume":"222","author":"Michels","year":"2005","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/j.ophtha.2006.10.038_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2006.10.038_bib40","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","article-title":"Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"26","author":"Rich","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2006.10.038_bib41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2006.10.038_bib42","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ophtha.2005.10.052","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled multidose study","volume":"113","author":"Heier","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2006.10.038_bib43","first-page":"53","article-title":"AMD treatment trends call attention to cost\/benefit considerations","author":"Nataloni","year":"2006","journal-title":"Retinal Physician"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164200601476X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164200601476X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:51:05Z","timestamp":1758981065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016164200601476X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S016164200601476X"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2006.10.038","relation":{},"ISSN":["0161-6420"],"issn-type":[{"type":"print","value":"0161-6420"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relative Cost of a Line of Vision in Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2006.10.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}